Boston Scientific Plans Taxus Element FDA Submission In Next Three Months
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific plans to submit a PMA for its third-generation platinum-chromium Taxus Element stent to FDA by June, relying on pivotal trial data reported March 15 at the American College of Cardiology meeting in Atlanta